About
IgniteData is transforming the future of clinical trials through its cloud-based data automation
technology, Archer. A system-agnostic solution, Archer delivers interoperability between electronic health
records (EHRs) and electronic data capture systems (EDCs) and other key research applications.
Providing the seamless, secure transfer of clinical data, Archer is the global EHR-to-EDC solution for modern clinical trials.
Archer is accredited as an EHR SMART-on-FHIR app by all major EHR vendors such as Epic, Cerner and Allscripts.
and harnesses the power of HL7 FHIR protocols, and SMART on FHIR APIs to allow data to be transferred remotely, without the need for hundreds of hours of manual effort re-keying data.
The time savings and efficiencies that Archer delivers are huge. In fact, around 20% of the total costs of a study (which can translate to between $16M-24M) is allocated to duplicating and verifying data.
Because Archer automatically transfers regulatory-grade data from the EHR into the study
database, it frees up time previously spent manually entering and validating data. Research
clinicians can spend their time on more valuable research tasks and run more studies. And
because productivity levels are transformed, hospital research sites can run more trials and
recruit more patients per study.
Key Facts
CEO Dan Hydes and CTO Richard Yeatman co-founded Berkshire-based IgniteData in 2014: they had the seed of an idea for a vendor-agnostic cloud-based system that would allow siloed data systems in healthcare and pharma to talk to each other. In particular, they wanted to build a tool that would facilitate the safe transfer of data from hospital Electronic Health Record systems (EHRs) to pharma sponsors’ Electronic Data Capture (EDC) systems, which are used to run clinical research studies. Now known as EHRto- EDC, this interoperability would address some of the enormous inefficiencies in how this process is done currently. In 2019, the co-founders judged that the technology landscape was right to begin building the world’s first truly agnostic EHR-to-EDC system. They secured a UK Government grant to build a prototype called Archer. Archer harnesses the power of HL7 FHIR protocols, and SMART on FHIR Application Programming Interfaces (APIs) to allow data to be transferred remotely, without the need for hundreds of hours of manual effort re-keying data. The impact of this new technology is huge. Recent studies have shown that, in a typical phase three oncology trial, an average of 3.6 million data points will be generated (three times the data collected by late stage trials 10 years ago). When each of these data points is copied in manually from one healthcare system to another pharma system, then crosschecked manually by up to two other people, it’s easy to see how the time and cost of this process quickly spirals. In fact, around 20% of the total costs of a study (which can translate to between $16M-24M) is allocated to duplicating and verifying data. Because Archer automatically transfers regulatory-grade data from the EHR into the study database, it frees up time previously spent manually entering and validating data. Research clinicians can spend their time on more valuable research tasks and run more studies. And because productivity levels are transformed, hospital research sites can run more trials and recruit more patients per study Archer benefits pharma sponsors as well: it reduces one of a study’s biggest cost centres enabling trials to reach Last Patient Last Visit and study database lock faster, which are important steps in getting treatments to patients that need them sooner. IgniteData’s Archer journey has seen the company forge relationships with leading pharmaceutical companies like AstraZeneca and hospitals such as University College London Hospitals (UCLH) to deploy Archer, in this example in 2021, to pilot the transfer of data from UCLH’s Epic EHR into AstraZeneca’s Medidata Rave EDC for a large oncology study. In February 2022, IgniteData announced a multi-million dollar partnership with ZS Associates. ZS’s investment as a minority investment partner in the business has developed into a deep partnership and strategic collaboration between our two organisations. From our initial trial sites across the UK, IgniteData is in conversations with sites and sponsors across the globe that are looking to streamline th
Successes in UK/NHS
UCLH implementationCompany details
Solutions
Driving insights and analysis
Enabling core infrastructure
Specialism
Data movement and interoperability
Drug discovery and Clinical trials
Company details
Want to connect with this innovator?
Make an enquiryWebsite
www.ignitedata.co.ukMarkets already exporting to
UK, Europe and USA
Desired Markets
UK, Europe and USA
Desired customer types
hospitals and pharma companies (sponsors)